TCEAL1 and prostate carcinoma: Rushworth et al. (2020) identified 17 candidate genes in prostate cancer whose inhibition may enhance the efficacy of docetaxel, with TCEAL1 (transcription elongation factor A-like 1) being the preferred candidate.